Connect with LRI:
Facebook
Twitter
YouTube
Change.org

Lupus Clinical Trials

New Medical Therapies™

Varicose Veins

February 6, 2012

BTG International reported results from a phase II trial of Varisolve microfoam for the treatment of varicose veins. This randomized, blinded trial, VANISH-2, enrolled 235 subjects with symptomatic and visible varicose veins and saphenofemoral junction incompetence who were randomized to treatment with one of three dose concentrations (0.125%, 0.5% or 1.0%) of Varisolve microfoam or placebo. The primary endpoint was an improvement in symptoms recorded using a patient-reported outcomes instrument, VVSymQ at eight weeks following treatment. The 0.5% and 1.0% dose concentrations of Varisolve microfoam demonstrated a statistically significant improvement in symptoms compared to placebo (p<0.0001). The subjects treated with Varisolve microfoam 0.5 and 1.0% also reported a statistically significant improvement in compared with placebo (p<0.0001 and p<0.0001, respectively). There were no serious or unexpected adverse events.

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.